A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.
To evaluate the efficacy, safety, and toleration of eplerenone in the treatment of children aged 6 to 16 years with high blood pressure. The study will last approximately 10 weeks and about 320 patients will participate.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Peds I (Pediatric Eplerenone Development Study I): A Randomized, Double-Blind, Placebo Withdrawal, Parallel Group, Dose-Response Study To Evaluate The Efficacy And Safety Of Eplerenone In The Treatment Of Hypertension In Children|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00147589
Show 41 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|